Medulloblastoma in adults: the path from diagnosis to treatment of relapse

As part of a retrospective study, we analyzed the results of complex treatment of 22 patients with a morphologically verified diagnosis of medulloblastoma who were treated at the "Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine" from 2012 to 2020. The average age of patients was 31.25 ± 8.4 years, the ratio of men and women was 2:1. Patients with desmoplastic variant of medulloblastoma prevailed (8 out of 22 patients). With a median follow-up of 52 months, a fatal outcome was recorded in two patients, in nine cases a relapse was detected, among them, in four patients in the area of the removed primary tumor and in five patients there were metastases within the central nervous system. The average time of relapse was 36.8 ± 7.14 months. At relapse, five patients underwent PCV polychemotherapy, and four patients underwent a course of stereotactic radiation therapy with the Cyber-Knife device. The best survival rates after treatment of a recurrent tumor were observed when chemotherapy was performed in an independent variant (1- year overall survival (OS) 62%); in the group of repeated radiation therapy, the indicators of 1-year OS were 54%.